Array BioPharma and Biogen Idec Collaborate on Kinase Inhibitors - - BioPharm International

ADVERTISEMENT

Array BioPharma and Biogen Idec Collaborate on Kinase Inhibitors


Array BioPharma will collaborate with Biogen Idec for the discovery and development of inhibitors targeting a novel kinase for the treatment of autoimmune disorders.  The collaboration target and lead inhibitors were discovered through Array's proprietary Kinase-Directed Phenotypic Screening Platform.  

"We are encouraged by the potential of this program to address inflammatory disease and are excited to add it to our immunology research portfolio," said Jo Viney, vice-president of Immunology Research, Biogen Idec.

Under the terms of the agreement, Biogen and Array will collaborate on the discovery of the novel kinase inhibitors. Biogen will be responsible for all aspects of clinical development and commercialization. The agreement includes research funding for three years, various milestone payments payable upon achievement of certain development and commercial milestones, and royalties to Array.

Source: Array Biopharma

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
New Report Details Players and Pipelines in the Biosimilar Space
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
FDA and NIH Win Award for IP Licensing of Meningitis Vaccine
September 26, 2014
Author Guidelines

Click here